Chindex Medical Acquires 10 ViewRay MRIdian® Systems for Advanced Cancer Treatment
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
DENVER, Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that Chindex Medical Limited (Chindex), through its subsidiary, has ordered 10 MRIdian® MR-Guided Therapy Systems. Chindex, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), has been ViewRay's distribution partner since 2019. MRIdian received regulatory approval in September 2022 from the National Medical Products Administration (NMPA), allowing for its sale and utilization throughout China. This approval expands MRIdian's global reach and offers cancer patients a new radiation
